GlaxoSmithKline weighs Bexsero's promise against gonorrhea by Eric Sagonowsky Tuesday, November 27, 2018 After a study showed meningitis B vaccines can protect against gonorrhea, Bexsero maker GSK is weighing whether its vaccine can fight the disease.
GSK renews Bexsero's back-to-college TV push by Beth Snyder Bulik Friday, August 31, 2018 GlaxoSmithKline's moms against meningitis B are back on the air in TV ads promoting its Bexsero vaccine for back-to-college.
4. Pfizer by Angus Liu Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
Hey, college-bound kids: Get your men B shot, GSK urges by Beth Snyder Bulik Wednesday, June 13, 2018 While you’re packing to leave for school, get vaccinated against meningitis B, GSK urges students in a new awareness push.
Glaxo's Shingrix should chip in $600M this year, execs say by Eric Sagonowsky Monday, April 30, 2018 GSK's Shingrix carried high expectations, but it turns out that even those ambitious projections weren't high enough.
Pfizer's Trumenba shot nabs 'breakthrough' tag for new use by Angus Liu Tuesday, April 24, 2018 The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
Merck's Gardasil 9 vaccine runs scarce in U.K. by Eric Sagonowsky Friday, April 13, 2018 Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.
GSK tops its peers with $7.16B in 2017 vaccine sales by Eric Sagonowsky Tuesday, February 13, 2018 While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.
Serum Institute talks up plan to go after blockbuster vaccines by Angus Liu Tuesday, December 12, 2017 Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.
Vaccines provide a boost for GSK, Sanofi and Merck in Q2 by Eric Sagonowsky Monday, July 31, 2017 For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.
